GleamWall
中文EN

CLPT ClearPoint Neuro, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1285550 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY32.5%
TTM net income YoY-56.2%
TTM EPS YoY-45.8%
Revenue 3-yr CAGR26.8%
Net income 3-yr CAGR—

Margins

Gross margin61.4%
Operating margin-70.6%
Net margin-79.4%
FCF margin-106.0%
EBITDA margin-69.3%

Returns

ROE-167.5%
ROA-41.8%
ROIC (approx.)-130.8%
Asset turnover0.53x

Leverage & solvency

Liabilities / assets75.8%
Debt / equity1.86x
Current ratio6.76x
Interest coverage-6.03x

Cash quality & payout

Operating cash flow / net income1.31x
Accruals ratio12.7%
Payout ratio—
Capex / revenue2.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$12.07M$10.88M$12.13M$10.41M$8.86M$9.21M$8.48M$7.77M
Cost of revenue$5.02M$4.17M$4.37M$4.01M$3.26M$3.66M$3.35M$3.01M
Gross profit$7.06M$6.71M$7.76M$6.40M$5.60M$5.56M$5.13M$4.76M
R&D expense$4.02M$4.63M$4.52M$3.24M$3.45M$3.83M$3.38M$3.33M
SG&A expense$3.84M$5.55M$5.00M$5.44M$3.59M$3.39M$4.08M$3.26M
Operating income-$6.33M-$10.24M-$8.48M-$7.04M-$5.28M-$5.68M-$6.16M-$5.64M
Interest expense$1.45M$1.41M$1.38M$1.08M$939,000$365,000$0—
Pretax income-$7.46M-$11.38M-$9.54M-$7.78M-$5.88M-$5.81M-$6.01M-$5.42M
Income tax-$4,000-$38,000$8,000$4,000$8,000$25,000$18,000-$32,000
Net income-$7.46M-$11.34M-$9.55M-$7.79M-$5.89M-$5.84M-$6.03M-$5.39M
EBITDA-$6.23M-$10.09M-$8.39M-$6.80M-$5.21M-$5.28M-$6.06M-$5.40M
EPS (basic)-0.24-0.38-0.32—-0.21-0.21-0.22—
EPS (diluted)-0.24-0.38-0.32—-0.21-0.21-0.22—
Weighted avg. shares (diluted)30.98M30.17M29.55M—28.43M28.26M27.72M—
Banking
Net interest income————-$543,000-$80,000$151,000$226,000
Balance sheet
Cash & equivalents$46.18M$29.36M$35.59M$45.92M$38.22M$41.54M$12.39M$20.10M
Receivables$8.02M$8.39M$8.66M$6.55M$4.00M$4.26M$3.65M$4.71M
Inventory$9.77M$8.81M$8.57M$8.36M$6.58M$6.29M$6.58M$6.86M
Current assets$66.71M$48.93M$54.88M$63.60M$51.33M$53.99M$24.21M$33.36M
PP&E, net$3.12M$2.99M$2.91M$2.62M$2.11M$2.02M$2.18M$2.00M
Goodwill$7.47M$7.47M$7.47M$7.47M———$7.47M
Intangibles$12.41M$12.91M$13.42M$13.92M———$0
Total assets$112.73M$86.74M$93.42M$97.75M$60.36M$62.87M$30.07M$39.19M
Current liabilities$9.87M$10.31M$9.48M$10.77M$8.05M$7.40M$6.87M$10.35M
Long-term debt$50.84M$50.23M$49.64M$49.08M$29.20M$28.84M——
Total debt$50.84M$50.23M$49.64M$49.08M$29.20M$28.84M——
Total liabilities$85.46M$75.97M$74.58M$69.73M$44.48M$43.13M$10.08M$13.80M
Shareholders' equity$27.27M$10.78M$18.84M$28.02M$15.87M$19.74M$19.99M$25.39M
Net debt$4.66M$20.87M$14.05M$3.15M-$9.02M-$12.70M——
Shares outstanding32.05M30.50M29.99M29.37M28.43M28.42M27.98M27.62M
Cash flow statement
Operating cash flow-$20.10M-$7.01M-$7.97M-$12.08M-$3.12M-$2.55M-$6.17M-$1.24M
Capital expenditure$137,000$214,000$645,000$49,000$199,000$91,000$183,000$263,000
Free cash flow-$20.24M-$7.23M-$8.61M-$12.13M-$3.32M-$2.64M-$6.36M-$1.51M
Investing cash flow-$137,000-$214,000-$645,000$1.09M-$199,000-$91,000-$183,000-$263,000
Financing cash flow$22.07M$1.00M-$1.84M$19.56M$0$31.98M-$1.36M$37,000
Depreciation & amortization$103,000$150,000$86,000$249,000$66,000$396,000$103,000$240,000
Stock-based compensation$1.88M$2.27M$2.22M$1.98M$2.02M$2.27M$1.91M$1.70M

Free plan shows the latest 8 periods; Pro shows all 63 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.